Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $4.5 to $5.
August 15, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs maintains a Neutral rating on Centessa Pharmaceuticals and raises the price target from $4.5 to $5. This could potentially influence the stock's performance in the short term.
The news directly pertains to Centessa Pharmaceuticals (CNTA). The raised price target by Goldman Sachs could potentially influence investor sentiment and the stock's performance. However, the Neutral rating suggests that the stock's price may not significantly change in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100